• Filter By:

A Deeper Dive into the REPRIEVE trial and the potential role of inflammation in residual risk
Patients living with HIV (PWH) have a 2-fold increase in the risk of developing coronary artery disease and myocardial infarction compared to those without HIV infection; this is due, in part, to a higher prevalence of traditional cardiovascular (CV) risk factors in these individuals, but also to chronic immune activation with inflammation, as well as direct viral effects1,2. Collectively, these insults result in early and aggressive atherosclerotic cardiovascular disease (ASCVD) by promoting dyslipidemia, endothelial dysfunction, atherogenesis, and thrombosis.
Source: Journal of Clinical Lipidology - September 20, 2023 Category: Lipidology Authors: Dinesh K. Kalra Tags: Editorial Source Type: research

Increased alcohol use during the COVID-19 pandemic among people with HIV from racial/ethnic minority groups in South Florida
.
Source: Journal of Ethnicity in Substance Abuse - September 20, 2023 Category: Addiction Authors: Daisy Ram írez-OrtizMelissa K. WardDiana M. SheehanSofia B. FernandezMichele Jean-GillesRobert LadnerMary Jo Trepkaa Department of Epidemiology, Florida International University, Miami, Florida, USAb Research Center in Minority Institutions, Florida Inte Source Type: research

Barriers and facilitators to implementing advanced HIV disease screening at a secondary referral hospital -Malawi: a convergent parallel study
Malawi continues to register HIV/AIDS mortality despite increased expansion of ART services and as well as advanced HIV screening as outlined in the 2020 -2025 Malawi National HIV Strategic Plan (NSP). This st...
Source: BMC Health Services Research - September 20, 2023 Category: General Medicine Authors: Brany Mithi, Agatha Bula, Lester Kapanda, Fatsani Ngwalangwa and Evanson Z. Sambala Tags: Research Source Type: research

Mechanisms and Clinical Significance of Pharmacokinetic Drug Interactions Mediated by FDA and EMA-approved Hepatitis C Direct-Acting Antiviral Agents
AbstractThe treatment of patients infected with the hepatitis C virus (HCV) has been revolutionised by the development of direct-acting antiviral agents (DAAs) that target specific HCV proteins involved in viral replication. The first DAAs were associated with clinical problems such as adverse drug reactions and pharmacokinetic drug –drug interactions (DDIs). Current FDA/EMA-approved treatments are combinations of DAAs that simultaneously target the HCV N5A-protein, the HCV N5B-polymerase and the HCV NS3/4A-protease. Adverse events and DDIs are less likely with these DAA combinations but several DDIs of potential clinica...
Source: Clinical Pharmacokinetics - September 20, 2023 Category: Drugs & Pharmacology Source Type: research

“Entre Nosotras:” a qualitative study of a peer-led PrEP project for transgender latinas
Uptake of HIV pre-exposure prophylaxis (PrEP) remains low among transgender people as compared to other subgroups, despite high rates of HIV acquisition. In California, Latinx people comprise 40% of the popula...
Source: BMC Health Services Research - September 20, 2023 Category: General Medicine Authors: Sophia Zamudio-Haas, Kim Koester, Luz Venegas, Ariana Salinas, Cinthya Herrera, Luis Gutierrez-Mock, Layla Welborn, Madeline B. Deutsch and Jae Sevelius Tags: Research Source Type: research

Association of TREX1 polymorphism with disease progression in human immunodeficiency virus type-1 (HIV-1) infected patients
AbstractThe time interval between HIV-1 infection and AIDS development is not the same in all patients and depends largely on the genetic background of the individual. Polymorphisms in theTREX1 gene, the main enzyme in the clearance of cytosolic DNA, affect type 1 interferon-mediated inflammatory response in HIV-1 infection. We aimed to study the role of a single nucleotide polymorphism (rs3135941) of theTREX1 gene and the rate of disease progression in patients infected with HIV-1. A total of 190 HIV-1 infected patients were recruited. Patients ’ demographic and laboratory data including CD4 counts, viral load, and anti...
Source: Virus Genes - September 20, 2023 Category: Genetics & Stem Cells Source Type: research

Viruses, Vol. 15, Pages 1961: The Antiviral Factor SERINC5 Impairs the Expression of Non-Self-DNA
th Serra-Moreno SERINC5 is a restriction factor that becomes incorporated into nascent retroviral particles, impairing their ability to infect target cells. In turn, retroviruses have evolved countermeasures against SERINC5. For instance, the primate lentiviruses (HIV and SIV) use Nef, Moloney Murine Leukemia Virus (MLV) uses GlycoGag, and Equine Infectious Anemia Virus (EIAV) uses S2 to remove SERINC5 from the plasma membrane, preventing its incorporation into progeny virions. Recent studies have shown that SERINC5 also restricts other viruses, such as Hepatitis B Virus (HBV) and Classical Swine Fever Virus (CSFV), al...
Source: Viruses - September 20, 2023 Category: Virology Authors: Yuhang Shi Sydney Simpson Shahad K. Ahmed Yuexuan Chen Aidin Tavakoli-Tameh Sanath Kumar Janaka David T. Evans Ruth Serra-Moreno Tags: Article Source Type: research

Distinctive model for HIV index testing (IT) in Eastern Europe: results of Ukraines physician-led, integrated IT programme
Conclusions There was a high case-finding index among ICs with recent HIV and high linkage to care for all partners, demonstrating the effectiveness of this integrated, physician-led model implemented in 39 health facilities in Ukraine.
Source: BMJ Open - September 20, 2023 Category: General Medicine Authors: Ihnatiuk, A. P., Shapoval, A. Y., Kazanzhy, A. P., Kuzin, I. V., Riabokon, S. V., Shotorbani, S., McDowell, M. R., Golden, M. R., Puttkammer, N. H. Tags: Open access HIV/AIDS Source Type: research

Newly diagnosed type 1 diabetes mellitus in a human immunodeficiency virus-infected patient with antiretroviral therapy-induced immune reconstitution inflammatory syndrome: a case report
Diabetes that develops in human immunodeficiency virus (HIV)-infected patients who receive antiretroviral therapy (ART) is usually type 2 diabetes mellitus (T2DM); however, autoimmune diabetes, such as type 1 ...
Source: BMC Infectious Diseases - September 20, 2023 Category: Infectious Diseases Authors: Min-ChunYeh, Han-Chuan Chuang, Shuen-Fu Weng, Chung-Huei Hsu, Chen-Ling Huang, Yu-Pei Lin, Yan-Yu Lin and Yu-Shan Hsieh Tags: Case Report Source Type: research

Small-area estimation and analysis of HIV/AIDS indicators for precise geographical targeting of health interventions in Nigeria. a spatial microsimulation approach
Precise geographical targeting is well recognised as an indispensable intervention strategy for achieving many Sustainable Development Goals (SDGs). This is more cogent for health-related goals such as the red...
Source: International Journal of Health Geographics - September 20, 2023 Category: International Medicine & Public Health Authors: Eleojo Oluwaseun Abubakar and Niall Cunningham Tags: Research Source Type: research

Understanding the social and structural context of oral PrEP delivery: an ethnography exploring barriers and facilitators impacting transgender women who engage in street-based sex work in Baltimore, Maryland
Transgender women who sell sex (TWSS) experience high rates of HIV acquisition. Antiretrovirals for pre-exposure prophylaxis (PrEP) represent an efficacious HIV prevention strategy. The social and structural f...
Source: AIDS Research and Therapy - September 20, 2023 Category: Infectious Diseases Authors: Erin E. Cooney, Katherine H. A. Footer, Jennifer L. Glick, Anna Passaniti, Meridian Howes and Susan G. Sherman Tags: Research Source Type: research

Mechanisms and Clinical Significance of Pharmacokinetic Drug Interactions Mediated by FDA and EMA-approved Hepatitis C Direct-Acting Antiviral Agents
AbstractThe treatment of patients infected with the hepatitis C virus (HCV) has been revolutionised by the development of direct-acting antiviral agents (DAAs) that target specific HCV proteins involved in viral replication. The first DAAs were associated with clinical problems such as adverse drug reactions and pharmacokinetic drug –drug interactions (DDIs). Current FDA/EMA-approved treatments are combinations of DAAs that simultaneously target the HCV N5A-protein, the HCV N5B-polymerase and the HCV NS3/4A-protease. Adverse events and DDIs are less likely with these DAA combinations but several DDIs of potential clinica...
Source: Clinical Pharmacokinetics - September 20, 2023 Category: Drugs & Pharmacology Source Type: research

Primary Care Can Lead Way to HIV Prevention Primary Care Can Lead Way to HIV Prevention
Primary care clinicians can provide optimal preventive care for patients at risk of contracting HIV.Medscape Medical News
Source: Medscape Allergy Headlines - September 19, 2023 Category: Allergy & Immunology Tags: Family Medicine/Primary Care News Source Type: news

For The Fight Against HIV, TB And Malaria, A Moment Of Reckoning
While the 17 SDGs present a sweeping vision for improving the lives of people across the world, progress against them is, at best, mixed.
Source: Forbes.com Healthcare News - September 19, 2023 Category: Pharmaceuticals Authors: Peter Sands, Contributor Tags: Healthcare /healthcare Innovation /innovation standard Source Type: news

Application of CMO (capacity, motivation, and opportunity) methodology in pharmaceutical care to optimize the pharmacotherapy in older people living with HIV. DISPIMDINAC project
CONCLUSIONS: The pharmaceutical intervention based onarmaceutical intervention based on the CMO methodology significantly decreased the prevalence of the PIMDINAC concept and increased the number of patients who achieved the objectives, optimising their pharmacotherapy.PMID:37724451 | DOI:10.37201/req/021.2023
Source: Revista Espanola de Quimioterapia - September 19, 2023 Category: Drugs & Pharmacology Authors: E S ánchez-Yáñez M J Huertas-Fern ández M A Robustillo-Cortes R Ramos-Guerrero S Fern ández-Espínola R Diaz-Acedo V Montero-Martin R Morillo-Verdugo Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20